Drug Trial Radar · NCT07544160
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Apr 7, 2026
Primary completion
Apr 7, 2028
Study completion Apr 7, 2028
Sponsor
- Lead sponsor
- iCell Gene TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- iCAR Bio Therapeutics Ltd.
- First posted
- Apr 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, IIa, Single-Arm, interventional, open label, treatment study to evaluate the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with relapsed and/or refractory inflammatory bowel disease.
Conditions
- Inflammatory Bowel Diseases (IBD)
Interventions
ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR TBiological
Anti-BCMA, Anti-CD19 Compound CAR-T cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs) after ICG318 CAR-T infusion.Time frame: Starting day 0 and up to 2 years after ICG318 CAR-T infusion.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan people's hospital
Zhongshan, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.